A case of acute drug-induced hepatotoxicity after albendazole treatment.
- Author:
Min Kwan KIM
1
;
Hye Won PARK
;
Won Jin KIM
;
Chul Min PARK
;
Ji Yeon HONG
;
Seung Jin CHO
;
Myoung Kuk JANG
Author Information
1. Department of Internal Medicine, Kangdong Sacred Heart Hospital, College of Medicine Hallym University, Seoul, Korea. mkjang2@medimail.co.kr
- Publication Type:Case Report
- Keywords:
Albendazole;
Hepatotoxicity
- MeSH:
Adult;
Alanine Transaminase;
Albendazole;
Aspartate Aminotransferases;
Autoantibodies;
Benzimidazoles;
Bilirubin;
Biomarkers;
Drug-Induced Liver Injury;
Humans;
Liver
- From:Korean Journal of Medicine
2008;75(5):564-568
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Drug-induced hepatotoxicity is injury to the liver as a result of drug exposure. Due to their unpredictable nature, drug-induced liver injuries pose a serious problem for clinicians, health agencies, and pharmaceutical firms. Albendazole is a benzimidazole with wide spectrum coverage as an antiparasitic drug. Very few cases of high-dose albendazole-induced hepatotoxicity have been reported so far, and no case in response to a single dose. A 25-year-old man presented to our hospital with dark urine. Twenty days prior to presentation, he took a tablet of albendazole (400 mg) as a prophylactic treatment for lumbricosis. Upon laboratory analysis, aspartate aminotransferase (AST) was 748 IU/L, alanine transaminase (ALT) was 939 IU/L, and total/direct bilirubin was 9.3/7.3 mg/dL. The patient was negative for viral markers (HAV, HBV, and HCV) and autoantibodies. Abdominal ultrasonography revealed no evidence of chronic liver damage. The pathology was compatible with drug-induced hepatotoxicity. The patient improved with conservative management only.
